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ABSTRACT
Expression of the tetraspanin CD151 is frequently upregulated in
epithelial malignancies and correlates with poor prognosis. Here, we
report that CD151 is involved in regulation of the expression of
fibroblast growth factor receptor 2 (FGFR2). Depletion of CD151 in
breast cancer cells resulted in an increased level of FGFR2.
Accordingly, an inverse correlation between CD151 and FGFR2
was observed in breast cancer tissues. CD151-dependent regulation
of the FGFR2 expression relies on post-transcriptional mechanisms
involving HuR (also known as ELAVL1), a multifunctional RNA-
binding protein, and the assembly of processing bodies (P-bodies).
Depletion of CD151 correlated with inhibition of PKC, a well-
established downstream target of CD151. Accordingly, the levels of
dialcylglycerol species were decreased in CD151-negative cells, and
inhibition of PKC resulted in the increased expression of FGFR2.
Whereas expression of FGFR2 itself did not correlate with any of the
clinicopathological data, we found that FGFR2−/CD151+ patients
were more likely to have developed lymph node metastasis.
Conversely, FGFR2−/CD151− patients demonstrated better overall
survival. These results illustrate functional interdependency between
CD151 complexes and FGFR2, and suggest a previously
unsuspected role of CD151 in breast tumorigenesis.
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INTRODUCTION
Tetraspanins represent a large group of four transmembrane domain
proteins with diverse biological activities (Berditchevski and
Rubinstein, 2013). At the biochemical level, tetraspanins are
thought to function as the main structural blocks and organizers
of distinct microdomains on the plasma membrane, which also
include transmembrane receptors (e.g. integrins, receptor tyrosine
kinases) and cytoplasmic signalling proteins. Analyses of clinical
material have suggested that several tetraspanin proteins may be
involved in the development and metastatic progression in various
cancer types (Hemler, 2014).
Expression of the tetraspanin CD151 is elevated in various types
of breast cancer, and this is correlated with poor prognosis and
overall survival in breast cancer patients (Kwon et al., 2012;
Novitskaya et al., 2014). Experiments involving cell lines and
animal models suggested that pro-tumorigenic and pro-metastatic
functions of CD151 are likely to be dependent on its ability to form
complexes with laminin-binding integrin receptors (i.e. α6β1, α3β1
and α6β4) and coordinate integrin-dependent signalling networks
in the context of receptor tyrosine kinases (Sadej et al., 2014).
Specifically, CD151 is known to regulate integrin ligand binding
and post-adhesion signalling, including activation of small GTPases
(Rho, Rac and Cdc42), FAK, Akt and Erk1/2 (Sadej et al., 2014).
The association with integrins is also important for CD151-
dependent regulation of cellular responses to growth factors and
inhibitory drugs that target receptor tyrosine kinases (RTKs) in
cancer cells (Deng et al., 2012; Novitskaya et al., 2014; Sadej et al.,
2010). Cross-talk between integrins and RTKs has been shown
to involve classical protein kinase C (PKC), well-established
molecular partners for several tetraspanin proteins including
CD151 (Li et al., 2013). In addition to regulating integrin
function, CD151 may influence the metastatic potential of cancer
cells indirectly via E-cadherin-based cell–cell adhesion complexes
(Johnson et al., 2009; Shigeta et al., 2003), or through the increased
production of extracellular matrix-degrading enzymes (e.g. matrix
metalloproteases) (Hasegawa et al., 2007).
FGFR2 is a member of a receptor tyrosine kinase subfamily that
also includes FGFR1, FGFR3 and FGFR4 (Kelleher et al., 2013).
There is increasing evidence that the FGF–FGFR2 signalling axis
plays an important role in breast cancer. Genome-wide analysis has
identified a number of single-nucleotide polymorphic (SNP)
variants in intron 2 of the FGFR2 gene that are associated with a
higher incidence of risk of breast cancer (Cui et al., 2016), and in
particular, in patients positive for hormonal receptors and negative
for Her2 (also known as ErbB2) (Cox et al., 2016). Several
transcription factors (e.g. FoxA1, Oct1 and E2F1) have been shown
to bind differentially to the high-risk alleles and, therefore, might be
responsible for elevated expression of FGFR2 in patients carrying
these alleles (Robbez-Masson et al., 2013). Furthermore, gene
amplification and overexpression of FGFR2 in breast cancer
tissues has been also described, particularly in the triple-negative
(i.e. ER−/PR−/ErbB2-negative) breast cancers (Turner et al., 2010).
Accordingly, overexpression and FGFR2 inhibitor studies using
human cell models supported the pro-tumorigenic function of
FGFR2 in breast cancer (Bai et al., 2010; Sommer et al., 2016). By
contrast, activation of FGFR2 inmouse primarymammary epithelial
cells resulted in activation of apoptosis (Xian et al., 2007). It was
also reported that FGFR2 inhibited epithelial-to-mesenchymal
transition and attenuated growth of human breast cancer
xenografts in vivo (Tarkkonen et al., 2012).Received 22 May 2018; Accepted 17 September 2018
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Here, we describe a new link between the tetraspanin CD151 and
FGFR2 in breast cancer. Specifically, we found that CD151 controls
the expression level of FGFR2 using a pathway that is independent
of proteolytic degradation or transcriptional regulation. Instead,
it involves the assembly of processing bodies (P-bodies) and
PKC-dependent signalling pathways. Importantly, the inverse
correlation between expression of CD151 and FGFR2 in cellular
models of breast cancer was also observed in breast cancer
tissues, thus emphasizing the importance of our findings for
future translational studies.
RESULTS
CD151 regulates expression of FGFR2
While analysing the expression of FGF receptors and tetraspanin
proteins in a panel of breast cancer cell lines, we noticed a tendency
for an inverse correlation between the levels of FGFR2 and CD151
(Fig. 1A). In these experiments, we detected no correlation between
expression levels of CD151 and FGFR1, on one hand, or between
FGFR2 and several other tetraspanins (i.e. CD9, CD63, CD81 and
CD82), on the other (Fig. 1A and data not shown). In agreement
with this observation, stable silencing of CD151 [herein depletion
or negative for expression is denoted by ‘(−)’ where wild-type
positive expression is denoted by ‘(+)’], but not CD63 or CD81,
resulted in increased FGFR2 levels in HB2 cells, a DCIS-like
mammary epithelial cell line, as well as in SKBR3 and MCF7
cells – two widely used breast cancer cell models (Fig. 1B and data
not shown). The re-expression of CD151 in HB2/CD151(−) cells
reverted the FGFR2 protein level to that observed in HB2/CD151(+)
cells, thus further excluding the off-target effect of the CD151
shRNA construct (Fig. 1C). An increased level of FGFR2 was
also observed when CD151 was targeted with an alternative
siRNA in transient knockdown experiments (Fig. S1). Importantly,
knockdown of CD151 had no effect on expression levels of FGFR1
or FGFR4 (FGFR3 was not detectable), emphasizing the specific
relationship between CD151 and FGFR2 (Fig. 1B).
Previous studies have demonstrated that most of CD151-
dependent regulation of cellular functions involves laminin-
binding integrins (α3β1 and α6 integrins) (Sadej et al., 2014).
Surprisingly, we found that depletion of these integrins in HB2
cells, either separately or in combination, had no effect on the
expression level of FGFR2 (Fig. 1D), thus demonstrating that the
CD151-dependent regulation of the FGFR2 expression does not
involve integrins.
Depletion of CD151 accentuates the responses of mammary
epithelial cells to FGFs
The initial proliferation experiments demonstrated that HB2/
CD151(+) and HB2/CD151(−) cells responded similarly to FGF2
and FGF9 when cultured under standard 2D conditions (Fig. S2
and data not shown). In contrast, the growth response of CD151-
depleted cells to FGFs was more robust when cells were placed in a
3D laminin-rich extracellular matrix (3D-lrECM) (Fig. 2A).
Furthermore, we noticed that FGF-treated HB2/CD151(−)
colonies lost their smooth ‘ball-like’ morphology and appeared
as disorganized aggregates of cells (Fig. 2A). Importantly,
re-expression of wild-type CD151 reversed the proliferative and
morphological phenotypes of HB2/CD151(−) cells (Fig. 2B).
Similarly, FGF-induced proliferation of CD151-depleted SKBR3
cells in 3D-lrECM was more pronounced when compared to
the control, SKBR3/CD151(+) cells (Fig. 2C). Analysis of the
Fig. 1. CD151 regulates expression of
FGFR2 gene. (A) An inverse correlation
between CD151 and FGFR2 expression
in a panel of breast cancer cell lines.
Protein lysates (20 µg) were resolved
by SDS-PAGE and expression levels of
CD151, CD81 and FGFR2 were analysed
by western blotting. Membranes were
stained with Ponceau S to control for the
amounts of loading material. Right panel
displays arbitrary density units (A.D.U.)
for FGFR2 and CD151 signals. The
Pearson’s correlation coefficient (r)
was calculated using Excel 2010.
(B) Knockdown of CD151 in mammary
epithelial cells results in a specific
increase of FGFR2 expression without
affecting other FGF receptors. Expression
of FGF receptors was analysed as
described in A. (C) Stable re-expression
of shRNA-resistant form of CD151 in
CD151-depleted cells (HB2/CD151rec)
reversed FGFR2 expression in HB2 cells.
(D) Silencing of α3 and α6 integrins does
not affect the expression level of FGFR2.
Expression of FGFR2 was analysed in
HB2 cells depleted of CD151 (lane 2),
α3 integrin subunit (lane 3), α6 integrin
subunit (lane 4) and (α3+α6) integrin
subunits (lane 5). HB2/CD151(+) cells
were used as a control. The middle panel
shows expression levels of α3 and α6
integrin subunits.
2
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs220640. doi:10.1242/jcs.220640
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
FGF-triggered signalling in HB2 cells growing in 3D-lrECM
revealed higher levels of phosphorylation of FRS2 and PLCγ
(specific downstream effectors of FGFR-triggered signalling) in
CD151-depleted cells (Fig. 2D). Taken together, these results
demonstrate that elevated FGFR2 levels in CD151-depleted
cells translate into more-prominent responses of breast cancer
cells to FGFs.
CD151 regulates expression of FGFR2 at the post-
transcriptional level
To investigate how CD151 controls the expression of FGFR2, we
initially examined the effect of inhibitors of various proteolytic
pathways. In these experiments, we found that treatment of HB2
cells with inhibitors of matrix metalloproteases (GM6001,
Batimastat), serine proteases (leupeptin), aspartic proteases
(pepstatin), calpains (calpastatin) and caspases (Z-VAD-FMK) did
not change expression levels of FGFR2 either in CD151-positive or
CD151-negative cells (Fig. S3 and data not shown). Likewise,
bafilomycin A1 and MG132, general inhibitors of endosomal/
lysosomal and proteosomal degradation have no notable effect
on FGFR2 levels in HB2/CD151(+) and HB2/CD151(−) cells
(Fig. S3 and data not shown). Therefore, we concluded that
CD151-dependent regulation of the FGFR2 expression does not
involve common proteolytic pathways.
Fig. 2. CD151 regulates cellular
responses to FGFs. HB2 (A,B) and
SKBR3 (C) CD151(+) and CD151(−) cells
were embedded in 3D lrECM and grown for
8 days in the presence of FGF2 and FGF9
(50 ng/ml). Representative images are
shown. Proliferation was measured by
using WST-1 reagent as described in the
Materials and Methods, and shown as
histograms in which bars represent
averaged results (mean±s.d.) of three
independent experiments. P values were
calculated using two-tailed t-test and are
indicated on graphs. Proliferation is
presented as percentage of the control,
CD151 cells grown under standard
culturing conditions. (D) Activation
(phosphorylation indicated by ‘p’ prefix)
of FGFR2-dependent signalling pathways
in cells grown under standard culturing
conditions was analysed by western
blotting. Shown representative results
of one of three independent experiments.
Scale bars: 100 μm.
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In further experiments, we compared the levels of FGFR2mRNA
in the control and CD151-depleted cells. Several probes covering
various parts of FGFR2 mRNA were used in quantitative RT-PCR
experiments to account for possible variations in FGFR2 splicing.
There were no differences observed between the control and
CD151-depleted cells in these experiments (Fig. S4), thus ruling out
the regulation at the level of mRNA.
Transcribed mRNAs bind a diverse range of nuclear proteins that
facilitate their export to the cytoplasm where the mRNP complexes
are either immediately translated or stored in various types of
cytoplasmic granules (Buchan, 2014). Thus, we examined whether
depletion of CD151 affected the assembly of stress granules (SGs),
P-bodies and GW bodies, the three most common types of RNA-
containing granules in eukaryotic cells. In these experiments, we
found that the number of P-bodies was noticeably reduced in CD151-
negative HB2 and SKBr3 cells (Fig. 3A). By contrast, the distribution
of TIA-1 (a SG marker) and GW182 (also known as TNRC6A;
a marker for GW bodies) was comparable in HB2/CD151(+) and
HB2/CD151(−) (results not shown). To examine the role of P-bodies
in FGFR2 expression directly, we silenced the expression of EDC4
and Pat1b, which have been shown to regulate the assembly of
P-bodies (Stalder and Mühlemann, 2009; Ozgur et al., 2010). As
illustrated in Fig. 3B, depletion of either protein increased FGFR2
levels. Therefore, we concluded that the elevated expression of
FGFR2 in CD151-negative cells is likely to involve P-bodies.
The mRNA-binding protein ELAVL-1/HuR is involved in
regulation of FGFR2 expression
Nuclear/cytoplasmic proteins TIA-1, TIAR (also known as TIAL1),
hnRNP-C1, hnRNP-C2 (hnRNP-C1/C2) and ELAVL-1 (also
known as HuR) have been shown to bind FGFR2 mRNA and are
known to be functionally linked to P-bodies (Izquierdo, 2010;
Del Gatto-Konczak et al., 2000; Hubstenberger et al., 2017; Stoecklin
and Kedersha, 2013; Lebedeva et al., 2011). Therefore, we examined
whether these proteins can be involved in CD151-dependent
regulation of expression of FGFR2 protein in breast cancer cells.
Total expression levels and nuclear versus cytoplasmic accumulation
of these proteins were comparable in CD151-positive and CD151-
negative cells (Fig. 4A). Knockdown of ELAVL-1 resulted in an
increased level of FGFR2 protein in HB2 and SKBr3 cells (Fig. 4B).
By contrast, the expression level of FGFR1 was not affected
(Fig. S5A). Furthermore, depletion of TIA-1, TIARor hnRNP-C1/C2
had no or aminimal effect on the expression levels of FGFR2 in either
CD151-positive or CD151-negative cells (Fig. S5B).
CD151-dependent regulation of FGFR2 expression
involves PKC
To examine the molecular mechanisms that could link CD151 with
the activity of ELAVL-1 towards FGFR2, we analysed signalling
pathways that are known to be regulated by tetraspanins, on one
hand, and affect the function of ELAVL-1, on the other.
Specifically, we compared activation of Src, p38 MAPK proteins
and PKC in the control and CD151-depleted HB2 cells. As
illustrated in Fig. 5A, the levels of active Src and p38 kinases were
comparable in HB2/CD151(+) and HB2/CD151(−) cells, thereby
ruling out the involvement of these proteins in CD151-dependent
regulation of FGFR2 expression. CD151 has been shown to
associate with classical protein kinases C (cPKC) (Zhang et al.,
2001). Interestingly, we found that the phosphorylation levels of
several cellular proteins recognized by the anti-phospho-(Ser) PKC
substrate antibody were higher in CD151(+) HB2 cells (Fig. 5B),
thus indicating that depletion of CD151 results in a lower basal level
of activation of PKC. Importantly, treatment of cells with
bisindolylmaleimide I (BIM I), a highly specific PKC inhibitor,
increased FGFR2 levels in both HB2 and SKBr3 cells (Fig. 5C).
Interestingly, treatment of HB2/CD151(+) cells with BIM I had no
effect on the assembly of P-bodies (Fig. S6). These results suggest
that, although activation of PKC is important for regulation of
FGFR2 expression by CD151, other pathways are responsible for
the effect of CD151 on the assembly of P-bodies.
It has been previously reported that when activated by phorbol
12-myristate 13-acetate (PMA) classical PKC form complexes with
various tetraspanin proteins including CD151 (Termini and Gillette,
2017). Thus, increased activation of PKC in CD151(+) breast cancer
cells might have been due to the association with tetraspanin
microdomains (or, more specifically, with CD151-containing
complexes). However, in accordance with previous studies, PKC
was not a part of the CD151 complexes purified from cells grown
under standard culturing conditions (Fig. S7). We therefore
considered whether increased PKC activation in CD151(+) cells is
Fig. 3. The effect of CD151 depletion on the formation of P-bodies, and the
role of P-bodies in the expression of FGFR2. (A) The number of P-bodies is
decreased in CD151-depleted cells. Cells were grown under standard culturing
conditions for 48 h before staining with the anti-EDC4 antibody to reveal
P-bodies. Representative images are shown. Numbers of P-bodies was
quantified in at least 70–100 cells. Scale bars: 10 μm. The graphs show
averaged results (mean±s.d.) of number of P-bodies per cell. P values were
calculated using two-tailed t-test. (B) Knockdown of the key components of
P-bodies (EDC4 and PatL1) increases FGFR2 expression. Cells were
depleted of EDC4 and PatL1 using specific siRNAs. si-Cont, control siRNA.
The expression of FGFR2 was assessed by western blotting 72 h after
transfection. Results of one of two independent experiments are shown.
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due to differences in the levels of diacylglycerol (DAG), the
physiological activator of classical and novel PKC. A quantitative
analysis of DAG species in HB2/CD151(+) and HB2/CD151(−)
cells revealed that depletion ofCD151 resulted in 1.5–2-fold decrease
in the levels of various DAGs species with the most pronounced
differences observed for 34:1, 36:1, 36:2 and 38:4 species (Fig. 5D).
Importantly, the effect of CD151 depletion on these DAGs was
specific, as we observed no differences in the levels of some other
species (e.g. 32:1 and 34:2). Although differences in the levels of
DAGs were not due to the activity of PLCγ (as monitored by the
phosphorylation levels of Tyr783) (Fig. 5E), we found that depletion
of CD151 resulted in changes in the intracellular distribution of
the enzyme with most cells losing their prominent PLCγ-positive
puncta/vesicles (Fig. 5F). Thus, we conclude that CD151-dependent
regulation of PKC activation and, subsequently, expression of
FGFR2 is controlled by the abundance of particular DAGs, which
may be caused by changes in compartmentalization of PLCγ.
An inverse relationship between FGFR2 and CD151, but not
the expression of FGFR2 alone, is associated with
invasiveness of breast cancer
To examine links between FGFR2 and CD151 further, we analysed
co-expression of these proteins in tissue samples from patients with
invasive ductal carcinoma (IDC) (Table 1). In the majority of both
normal mammary glands and tumours, expression of FGFR2 was
highly heterogeneous. Various patterns of FGFR2 immunostaining,
that is, cytoplasmic and/or membranous (39%; 65/166), nuclear
(45%; 75/166) or ubiquitous (23%; 38/166) could be seen. There
was no association between levels of FGFR2 immunoreactivity in
distinct cellular compartments. A highly heterogeneous pattern of
immunoreactivity was also observed when expression of FGFR2
was analysed in combination with immunoreactivity for CD151. An
inverse relationship (i.e. expression of either FGFR2 or CDC151 but
not both) between FGFR2 and CD151 expression was seen in many
samples, with 51/166 (31%) being FGFR2(−)/CD151(+) and 38/
166 (23%) being and FGFR2(+)/CD151(−), respectively. In 50/166
cases (30%) tumours were negative for both FGFR2 and CD151,
while a FGFR2(+)/CD151(+) trait was found in a minority of
samples (27/166; 16%). Importantly, a Kendall’s test demonstrated
a nonlinear negative correlation between cytoplasmic/membranous
FGFR2 and CD151 (τ=0.14, P=0.029), thus supporting the inverse
relationship between FGFR2 and CD151 levels in breast cancer
cells. Expression of nuclear FGFR2 alone did not correlate with any
of the tumour characteristics and cytoplasmic/membranous FGFR2
was significantly associated only with lack of hormone receptors
(P=0.04) (Table 1). However, when assessed in combination with
CD151, an inverse FGFR2/CD151 expression in tumour cells was
significantly correlated with clinicopathological variables such as
grade [FGFR2(+)/CD151(−) versus rest of the samples; P=0.012]
and nodal status [FGFR2(−)/CD151(+) versus rest of the samples;
P=0.037] (Tables 1 and 2). The FGFR2(−)/CD151(+) phenotype
was also more frequently seen in the triple-negative subgroup of
the studied cohort (P=0.039) (Table 1). Expression of FGFR2 alone
(either cytoplasmic/membranous or nuclear) was of no prognostic
value (Fig. 6A). Interestingly, its absence from the cell, when
combined with lack of CD151 expression [FGFR2(−)/CD151(−)],
not only inversely correlated with nodal status (P=0.013) and HER2
(P=0.014) (Tables 1 and 2), but also proved a good prognostic
indicator (P=0.024) (Fig. 6B), albeit not independent (results of
multivariate analysis not shown).
DISCUSSION
Dysregulation of the FGF–FGFR2 signalling network is thought to
play an important role in various epithelial malignancies (Katoh and
Nakagama, 2014). Point mutations, gene amplification, tumour-
associated alternative splicing and gene rearrangements can lead to
changes in FGFR2 function (Fearon et al., 2013; Katoh, 2008, 2009;
Wu et al., 2013). Here, we show for the first time that the expression
of FGFR2 in breast cancer cells is controlled by CD151-based
signalling complexes. Importantly, we establish that CD151-
dependent post-transcription regulation of FGFR2 expression is
specific (i.e. CD151 does not regulate expression of FGFR1 or
FGFR4) and involves PKC.
Importantly, in agreement with our in vitro observation, an inverse
correlation between expression of CD151 and FGFR2 was also seen
Fig. 4. The role of ELAVL-1 in CD151-dependent regulation of FGFR2
expression. (A) Expression levels and distribution of mRNA-binding proteins
in HB2 cells was analysed by western blotting using specific antibodies. WCL,
whole cell lysates; cytopl. and nuclear, cytoplasmic and nuclear fractions of the
proteins, respectively. Note, HSP90 is only found in the cytoplasmic fractions.
(B) The effect of ELAVL-1 (HuR) siRNA (two different siRNAs indicated by
si-HuR/1 and siHuR/2) knockdown on the FGFR2 expression in HB2 and
SKBr3 cells. The expression of FGFR2 was assessed by western blotting 72 h
after transfection. Shown results of one of the two independent experiments.
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in the tumour tissues. These results imply that the pathway(s) that link
expression of these proteins are also operational in vivo. Expression of
FGFR2 alone did not have any prognostic value, which confirms our
recent observations (Czaplinska et al., 2016). Although hormone
receptors were the only clinicopathological feature associated with
FGFR2, in contrast to the previous study, its relationship was inverse.
The discrepancy between these results may reflect differential roles
played by FGFR2 in distinct subtypes of breast carcinoma, as unlike
findings shown by Czaplinska and colleagues, our analysis was
performed on a histologically homogeneous group of specimens (i.e.
invasive ductal carcinoma). In the patients with inverse correlation of
CD151 and FGFR2 expression, only those that expressed high levels
of CD151 [i.e. FGFR2(−)/CD151(+)] demonstrated correlation with
lymph node involvement. Interestingly, a cohort of FGFR2(+)/
CD151(+) patients did not show such correlation, which suggests that
the presence of FGFR2 may suppress prometastatic activity of
CD151. Indeed, this and previous studies (Klosek et al., 2009; Kwon
et al., 2012) have revealed a highly significant correlation between the
expression of CD151 and metastasis to the lymph nodes. Conversely,
it was only in the absence of FGFR2 expression that CD151-negative
cancer cells [FGFR2(−)/CD151(−) cohort] were less likely to be
found in the lymph nodes. These results suggest that the proposed
prometastatic function ofCD151 in breast and, possibly, other cancers
should be assessed in the context of FGFR2 expression.
Fig. 5. The role of PKC in CD151-
dependent regulation of the FGFR2
expression. (A) Activation of p38 MAPKs
and Src (phosphorylation indicated by
‘p’ prefix) in cells grown under standard
culturing conditions was analysed by
western blotting using appropriate
phosphorylation-specific antibodies.
Histogram shows compilation of
densitometric measurements of three
independent experiments. R.D.U., relative
density units. (B) Activation of PKC in cells
grown under standard culturing conditions
was analysed by western blotting using
anti-phospho-(Ser) PKC substrate antibody.
(C) Cells were grown under standard
culturing conditions in the presence of BIM-I
for 72 h and the expression of FGFR2 was
assessed by western blotting. Shown is a
representative image of three independent
experiments. (D) Determination of DAG
species (DG species) present. The
concentrations of individual DAG molecular
species were determined by mass
spectrometry in HB2/CD151(+) (closed
bars) and HB2/CD151(−) cells (open bars),
and normalized to cellular DNA content.
Results are mean±s.d. (n=4). (E) Activation
of PLCγ was assessed by western blotting
using anti-phospho-PLCγ (Tyr783) antibody
in three independently prepared cellular
lysates. Shown are the mean±s.d. ratio for
the signal intensities of phPLCγ to total
PLCγ. (F) Distribution of PLCγ in HB2/
CD151(+) and HB2/CD151(−) cells. Cells
were grown under standard culturing
conditions for 48 h before staining with the
anti-PLCγ antibody. Representative images
are shown. Scale bar: 10 μm.
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We discovered that CD151-dependent regulation of FGFR2
expression occurs at the post-transcriptional level via the
mechanisms involving P-bodies. P-bodies are ribonucleoprotein-
containing cytoplasmic aggregates that are known to control mRNA
stability and translation (Anderson et al., 2015). The involvement of
P-bodies adds a new layer of complexity to regulation of FGFR2
expression. Our data strongly suggest that ELAVL-1 is likely to be a
critical downstream component of the CD151-dependent signalling
network that is targeting FGFR2 mRNA. In other experiments,
we found that FGFR2 is not the only target for ELAVL-1 in
HB2 cells: expression levels of both c-Myc and cyclin E, two
previously identified targets for ELAVL-1 were also increased in
HB2/CD151(−) cells (Fig. S8). These results suggest that CD151-
dependent regulation of the ELAVL-1 function may have wider
consequences for CD151-positive breast cancer cells.
ELAVL-1 is a widely expressed multifunctional RNA-binding
protein that was shown to regulate alternative splicing, mRNA
stability and translation by binding to AU-rich elements (AREs) in
the 3′- and 5′-untranslated regions of multiple mRNAs (Lebedeva
et al., 2011; Uren et al., 2011). Although specific involvement of
ELAVL-1 in regulation of FGFR2 expression has not been reported
previously, the FGFR2 mRNAwas identified in the transcriptome-
wide screen for potential ELAVL-1 targets (Lebedeva et al., 2011).
Furthermore, a recent report by Hubstenberger and colleagues
demonstrated that ELAVL-1 and FGFR2 mRNA segregate to
P-bodies (Hubstenberger et al., 2017). Alternatively, ELAVL-1 can
control the expression and/or alternative splicing of various proteins
whose function is directly linked to the P-body assembly (Lebedeva
et al., 2011; Uren et al., 2011).
RNA binding and nuclei-cytoplasm shuttling of ELAVL-1 are
controlled by various post-translational modifications of the protein
that involve a multitude of signalling pathways (Eberhardt et al.,
2012; Grammatikakis et al., 2017). Our data suggest that CD151
regulates the activity of the protein via a PKC-dependent signalling
pathway. A functional link between CD151 and cPKC has been
demonstrated in two earlier studies (Li et al., 2013; Shigeta et al.,
2003). Although not directly examined, both reports suggested that
the expression of CD151 is correlated with the increased activity of
cPKC towards their substrates. By using antibodies that detect
phosphorylation of PKC substrates as our biochemical readout, we
demonstrated that the activity of PKC is, in fact, suppressed in
CD151-depleted cells. This poses an important question regarding
Table 1. Relationship between clinicopathological features and expression of (1) FGFR2 alone and (2) FGFR2 in association with CD151
Feature
FGFR2(+) (n=65)
vs rest (n=101)
FGFR2(+)/CD151(−)
(n=38) vs rest (n=128)
FGFR2(−)/CD151(+)
(n=55) vs rest (n=111)
FGFR2(+)/CD151(+)
(n=27) vs rest (n=139)
FGFR2(−)/CD151
(n=50) vs rest (n=116)
Tumour size 0.131 0.344 0.164 0.487 0.839
Nodal status 0.724 0.933 0.037 0.574 0.013
Stage 0.510 0.366 0.114 >0.999 0.369
Grade 0.095 0.012 0.102 0.510 0.895
HER2 0.197 0.771 0.281 0.171 0.014
ER/PR 0.040 0.221 0.066 0.185 0.736
TN 0.293 0.595 0.039 0.437 0.333
ER, oestrogen receptor; PR, progesterone receptor. Statistically significant correlation is shown in bold.
Fig. 6. Kaplan–Meier curves of overall survival for patients with breast
cancer. (A) Patients expressing cytoplasmic/membranous FGFR2 compared
with FGFR2-negative patients. (B) Patients negative for both FGFR2 and
CD151 [FGFR2(−)CD151(−)] compared with the rest of the cohort.
Table 2. Univariate analysis of prognostic factors
Factor Hazard ratio 95%CI P value
FGFR2 1.25 0.75-2.07 0.383
CD151 1.80 1.08-3.01 0.023
FGFR2(+)/CD151(−) 0.95 0.52-1.73 0.87
FGFR2(−)/CD151(+) 1.45 0.87-2.44 0.16
FGFR2(+)/CD151(+) 1.54 0.84-2.84 0.17
FGFR2(−)/CD151(−) 0.47 0.24-0.91 0.024
Tumour size (T1 vs T2–T4) 1.77 1.30-2.40 <0.001
Nodal status 3.01 1.78-5.10 <0.001
Stage (I vs II vs III) 1.81 1.27-2.57 <0.001
ER/PR 0.53 0.33-0.87 0.011
HER2 2.07 1.18-3.64 0.012
Grade (G1–2 vs G3) 1.24 0.76-2.01 0.383
Statistically significant correlation is shown in bold.
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the nature of the functional and physical links between cPKC and
CD151 and how the removal of the tetraspanin can affect the activity
of the enzymes. Previous biochemical studies have shown that the
interaction between tetraspanins and cPKC occurs only under the
acute cell stimulation with PMA (Gustafson-Wagner and Stipp,
2013; Zhang et al., 2001), or upon activation of EGF or B-cell
receptors (Deng et al., 2012; Zuidscherwoude et al., 2017). Here, we
demonstrate for the first time that a tetraspanin protein affects PKC-
dependent signalling even under standard/basal growth conditions
when the association between the proteins is not detected (Fig. S5).
This observation indicates that a physical link between CD151 and
cPKC is not necessary for the tetraspanin to modulate the activity
of the enzymes towards their targets. Rather, it is likely that,
functionally, CD151 (and possibly other tetraspanins) are linked to
cPKC indirectly. Indeed, we show here for the first time that the
removal of CD151 in breast cancer cells decreases the abundance of
particular species of DAG. The importance of this observation is
that it is not a general change in all DAG species, but rather specific
changes in individual molecular species that is observed. We have
previously discussed the differential regulation of signalling by
distinct DAG species (Wakelam, 1998). Furthermore, our data
indicate that the effect of CD151 on the production of DAGs (at
least, some of the DAG species) may be linked with redistribution of
PLCγ. Thus, we propose that CD151 affects the activity of PKC by
regulating either biosynthetic or catabolic pathways linked to the
generation of DAGs. Further investigation will be necessary to
pinpoint how these pathways are directly targeted by the tetraspanin.
In summary, we discovered a novel mechanistic link between the
CD151 complex and FGFR2. The data demonstrate that, in addition
to their well-established role as post-translational regulators of
protein expression, tetraspanins are also involved in regulation
of protein expression at the post-transcriptional level. Future
investigation into molecular pathways responsible for tetraspanin-
dependent regulation of FGFR2 expression will further define the
functional interdependence of tetraspanin microdomains and
FGFR2 in the context of breast cancer.
MATERIALS AND METHODS
Cell lines, antibodies and reagents
HB2/CD151(+), HB2/CD151(−), HB2/α3(−), HB2/α6(−), SKBR3/
CD151(+), SKBR3/CD151(−), MCF7/CD151(+) and MCF7/CD151(−)
cells were described previously (Baldwin et al., 2008; Novitskaya et al.,
2010, 2014). The HB2/CD151rec cell line was established after
transfections of HB2/CD151(−) cells with the construct encoding the
shRNA-resistant form of CD151 (Novitskaya et al., 2014). Antibodies
against FGFR1 (sc-121), FGFR2 (sc-122), FGFR4 (sc-124), Src (sc-18) and
TIA-1 (sc-1751) were from Santa Cruz Biotechnology. All antibodies from
Santa Cruz Biotechnology were used at the dilution 1:400. Antibodies
against β-actin (A5316, used at 1:10,000) were purchased from Sigma-
Aldrich; all phospho-specific antibodies [phospho (Ser) PKC substrate
(#2261), phospho Src family (Tyr 416) (#2113), phospho p38 (T180/Y182)
(#9215) and phospho-PLCgamma1(Y783)(#2821)] and antibodies to
EDC4/Ge-1 (#2548), PatL1 (#14288), TIAR (#8509), hnRNP C1/C2
(#12392) and ELAVL-1 (#12582) were from Cell Signaling Technologies.
All antibodies from Cell Signaling Biotechnology were used at the dilution
1:500. All growth factors were purchased from Peprotech; laminin-rich
extracellular matrix (lrECM) Matrigel, was from BD Bioscience.
Culturing of cells in 3D lrECM
Culturing cells in 3D-lrECM was performed as previously described (Sadej
et al., 2009). Briefly, 1.5×103 cells were resuspended in 40 µl of growth
factor reduced lrECM:DMEM (1:1). Solidified lrECM drops were covered
with medium containing 2% fetal bovine serum (FBS) and supplemented,
when needed, with FGFs (50 ng/ml). For morphological analyses in 3D
culture experiments, pictures were taken using a Zeiss Primovert microscope
coupled with an AxioCam ERc 5s camera (Zeiss). Cell proliferation in 3D
was measured using WST-1 reagent (tetrazolium salts) according to the
manufacturer’s protocol (Roche). Experiments were performed in duplicate,
and at least three independent experiments were performed for each
experimental condition. Comparative data were analysed with an unpaired
Student’s t-test using the Statistica 7.1 software. Differences for which
P<0.05 were considered as statistically significant.
Western blotting
Cells grown to 80–90% confluence were lysed in Laemmli buffer
supplemented with 2 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin,
5 mM EGTA, 1 mM EDTA, 2 mM Na4P2O7, 5 mM NaF and 5 mM
Na3VO4. Samples containing equal amounts of protein per lane were loaded
and resolved on 10% SDS-PAGE and then transferred onto nitrocellulose
membrane. The membranes were incubated for 1 h in 5% skimmedmilk and
probed with specific antibodies overnight. The infrared-tagged secondary
antibodies were used to visualize the signals, and the images were captured
and quantified using a LI-COR Odyssey scanning system.
siRNA-based knockdown
Cells were transfected with control or gene-targeting siRNAs (20 nM) using
Lipofectamine®RNAiMAX transfection reagent (ThermoFisher). The
expression level of FGFR2 was assessed by western blotting at 72 h after
transfection. For immunofluorescence experiments, cells were plated on
coverslips the day before transfection and analysed 72 h after transfection.
All siRNAs were purchased from Qiagen in the Flexitube format; target
sequences are shown in Table S1.
Immunofluorescence staining
Cells grown on glass coverslips were fixed with 4% paraformaldehyde and
permeabilized using 0.1% Triton X-100. Staining with rabbit anti-EDC4
antibody (diluted at 1:200) was carried out according to the manufacturer’s
recommendations. P-bodies were quantified in 50–100 cells in two or three
independent experiments. For staining using anti-PLCγ1 antibody (diluted
at 1:100, Cell Signaling Technology, #2282) cells were permeabilized for
1 h in 1%Brij98.
Real-time qPCR
Total RNAwas isolated from HB2 cells using the RNAeasy kit according to
the manufacturer’s instructions (Qiagen, Crawley, United Kingdom). The
cDNAswere synthesized fromRNA (1 µg) byMultiScribe™MuLV reverse
transcriptase (Life Technology, Paisley, UK). Real-time quantitative
(q)PCR was carried out using either commercial TaqMan or custom-
designed SYBRGreen primers (sequences are available upon request). PCR
conditions were as follows: (1) 95°C for 10 min; (2) 40 cycles of 95°C for
15 s and 60°C for 1 min. At least three separate PCR experiments for each
gene were performed. The real-time amplification data were analysed using
REST software (Qiagen, Crawley, UK) and gene expression levels were
normalized relative to that of the controlGAPDH gene for the TaqMan assay
or β-actin for the SYBR green assay.
Diacylglycerol analysis by mass spectrometry
Frozen cell pellet lipids were extracted using the Folch method with
chloroform:methanol:water (2:1:1 ratio) and resuspended in chloroform:
methanol (1:1) prior to injection into a Shimadzu Prominence 20-AD system
(Shimadzu, Kyoto, Japan). Chromatographic separation was achieved upon
a Waters Acquity UPLC C4 (100×1 mm, 1.7 µm particle size) column
(Milford, MA). The column was kept at 45°C, and 7 µl of samples were
eluted using a mobile phase composed of solvent A (water) and B
(acetronitile) each containing 0.025% formic acid. The gradient started at
45% B (5 min), with an increase to 90% B for 5 min; 100% B was reached
after an additional 10 min and held for 7 min before re-equilibration at 45%
B for 5 min. The flow rate was maintained constant at 100 µl/min. Accurate
mass (with an error below 5 ppm) was acquired on an Orbitrap Elite mass
spectrometer (Thermo Fisher Scientific, Waltham, MA). Source parameters
for positive polarity were: capillary temperature, 275°C; source heater
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temperature, 200°C; sheath gas, 10 AU; aux gas, 5 AU; and sweep gas,
5 AU. The source voltage was 3.8 kV. Full scan spectra in the range of m/z
150 to 1000were acquired at a target resolution of 240,000 [full width at half
maximum (FWHM) at m/z 400]. Data analysis was performed using Lipid
Data Analyzer (2.6.0_2) software (Hartler et al., 2017).
Patient selection and samples
Patient selection and samples are described in Table S2. Specimens of
primary invasive ductal carcinoma from women treated in the Oncology
Department of the Copernicus Memorial Hospital in Lodz, Poland between
2003 and 2010 were obtained according to the local ethical regulations
(License No. RNN/174/11KE, Medical University of Lodz 2011) and
according to the principles expressed in the Declaration of Helsinki (2000).
This is archival material and no consent specific for this study was required.
Immunohistochemistry
Serial 5 µm paraffin sections of archival formalin-fixed blocks were
processed for immunohistochemistry for FGFR2 (rabbit anti-human;
1:100; Santa Cruz Biotechnology) and CD151 (mouse anti-human; 1:100;
Novocastra, UK) using routine protocols described previously (Novitskaya
et al., 2014). As a negative control for immunostaining, primary antibodies
were replaced by nonimmune sera. Scoring immunoreactivity for FGFR2
was carried out separately for cytoplasmic/membranous and nuclear
FGFR2 expression. Cytoplasmic/membranous expression of FGFR2 was
considered: (1) 0/negative, if no reactivity, (2) 1+/positive, if weak to
moderatemembranous and/or cytoplasmic stainingwas observed in <10%of
tumour cells; (3) 2+/positive, if moderate membranous and/or cytoplasmic
staining was observed in≥10% of tumour cells; and (4) 3+/positive, if strong
membranous and/or cytoplasmic staining was observed in ≥10% of the
tumour cells. Assessment of nuclear immunoreactivity was based on
Quick score (Detre et al., 1995). Scoring of immunoreactivity for CD151was
performed as described previously (Novitskaya et al., 2014).
Immunohistochemical staining was assessed independently by two
observers (H.R.-K. andR.K.) whowere blind to the clinicopathological data.
Statistical analysis
Overall survival was calculated from the date of surgery to the date of death
or the last follow-up, as recommended by the Kaplan–Meier method.
Differences in survival distributions were compared using a log-rank test.
Data for patients who died from other causes than breast cancer were
censored at the time of death. Univariate and multivariate analyses of overall
survival were performed using the Cox’s proportional hazards regression
model. Pearson’s test or Fisher’s exact test were used to assess the
associations between expression of FGFR2 and CD151 alone and their co-
expression and clinicopathological variables. Kendall’s tau rank correlation
test was used to study correlation between levels of FGFR2 and CD151
expression in cancer tissue. The results were considered statistically
significant when a two-sided test gave P<0.05. The analyses were
performed using the StatsDirect (StatsDirect Ltd, Altrincham, UK) and
Statistica 9.1 (StatSoft Inc., Tulsa, OK, USA) software.
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M., Odintsova, E. and Berditchevski, F. (2014). Integrin alpha3beta1-CD151
complex regulates dimerization of ErbB2 via RhoA. Oncogene 33, 2779-2789.
Ozgur, S., Chekulaeva, M. and Stoecklin, G. (2010). Human Pat1b connects
deadenylation with mRNA decapping and controls the assembly of processing
bodies. Mol. Cell Biol. 30, 4308-4823. Epub 2010 Jun 28.
Robbez-Masson, L. J., Bödör, C., Jones, J. L., Hurst, H. C., Fitzgibbon, J., Hart,
I. R. and Grose, R. P. (2013). Functional analysis of a breast cancer-associated
FGFR2 single nucleotide polymorphism using zinc finger mediated genome
editing. PLoS ONE 8, e78839.
Sadej, R., Romanska, H., Baldwin, G., Gkirtzimanaki, K., Novitskaya, V., Filer,
A. D., Krcova, Z., Kusinska, R., Ehrmann, J., Buckley, C. D. et al. (2009).
CD151 regulates tumorigenesis bymodulating the communication between tumor
cells and endothelium. Mol. Cancer Res. 7, 787-798.
Sadej, R., Romanska, H., Kavanagh, D., Baldwin, G., Takahashi, T., Kalia, N.
and Berditchevski, F. (2010). Tetraspanin CD151 regulates transforming growth
factor beta signaling: implication in tumormetastasis.Cancer Res. 70, 6059-6070.
Sadej, R., Grudowska, A., Turczyk, L., Kordek, R. and Romanska, H. M. (2014).
CD151 in cancer progression and metastasis: a complex scenario. Lab. Invest.
94, 41-51.
Shigeta, M., Sanzen, N., Ozawa, M., Gu, J., Hasegawa, H. and Sekiguchi, K.
(2003). CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-
dependent actin cytoskeletal reorganization. J. Cell Biol. 163, 165-176.
Sommer, A., Kopitz, C., Schatz, C. A., Nising, C. F., Mahlert, C., Lerchen, H.-G.,
Stelte-Ludwig, B., Hammer, S., Greven, S., Schuhmacher, J. et al. (2016).
Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982
for the treatment of FGFR2-positive solid tumors. Cancer Res. 76, 6331-6339.
Stalder, L. and Mühlemann, O. (2009). Processing bodies are not required for
mammalian nonsense-mediated mRNA decay. RNA 15, 1265-1273.
Stoecklin, G. and Kedersha, N. (2013). Relationship of GW/P-bodies with stress
granules. Adv. Exp. Med. Biol. 768, 197-211.
Tarkkonen, K. M., Nilsson, E. M., Kähkönen, T. E., Dey, J. H., Heikkilä, J. E.,
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